Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results

被引:155
作者
Yamazaki, Taizo [1 ]
Koizumi, Hideki [1 ]
Yamagishi, Tetsuya [1 ]
Kinoshita, Shigeru [1 ]
机构
[1] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan
关键词
RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF TREATMENT; INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; VASCULOPATHY; VERTEPORFIN; INJECTION; FRAGMENT;
D O I
10.1016/j.ophtha.2012.02.022
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To investigate the changes in subfoveal choroidal thickness after intravitreal injections of ranibizumab (IVRs) for neovascular age-related macular degeneration (AMD). Design: Prospective, consecutive, interventional case series. Participants: Eighty eyes (40 affected eyes with neovascular AMD and 40 unaffected fellow eyes) of 40 patients. Methods: Forty eyes with neovascular AMD were treated with 0.5-mg IVRs monthly for 3 months and received additional IVRs as needed over the following 9-month period. Subfoveal choroidal thickness in all 80 eyes was measured by use of enhanced depth imaging optical coherence tomography images before and after starting the IVRs. Main Outcome Measures: Changes in subfoveal choroidal thickness after treatment by IVRs over a 12-month period. Results: Twenty-three eyes (57.5%) were diagnosed with typical neovascular AMD, 16 eyes (40%) were diagnosed with polypoidal choroidal vasculopathy, and 1 eye (2.5%) was diagnosed with retinal angiomatous proliferation. Fifteen eyes (38%) had received some previous treatments for the neovascular lesion before undergoing the IVRs. The mean best-corrected visual acuity of the affected eyes was improved from 0.54 logarithm of the minimum angle of resolution units at baseline to 0.42 at 12 months (P = 0.020). The mean subfoveal choroidal thickness in the affected eyes decreased from 244 +/- 62 mu m at baseline to 234 +/- 66 mu m at 1 month (P = 0.013), 226 +/- 68 mu m at 3 months (P<0.001), 229 +/- 67 mu m at 6 months (P = 0.002), and 226 +/- 66 mu m at 12 months (P = 0.002; the change ratio, 93%), whereas that in the unaffected eyes changed from 237 +/- 80 mu m at baseline to 238 +/- 83 mu m at 12 months (P = 0.78). In the affected eyes, the change ratio of subfoveal choroidal thickness at 12 months was not correlated with the number of IVRs (mean, 5.8 +/- 2.9). Subfoveal choroidal thickness demonstrated a similar trend toward decreasing during the following period independent of the subtypes of neovascular AMD or the treatment histories. Conclusions: Subfoveal choroidal thickness decreased after IVRs in eyes with neovascular AMD. Intravitreal injections of ranibizumab may provide a pharmacologic effect not only on the neovascular lesion but also on the underlying choroid. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1621-1627 (C) 2012 by the American Academy of Ophthalmology.
引用
收藏
页码:1621 / 1627
页数:7
相关论文
共 45 条
  • [21] INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHY
    Lai, Timothy Y. Y.
    Lee, Gary K. Y.
    Luk, Fiona O. J.
    Lam, Dennis S. C.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (08): : 1581 - 1588
  • [22] INTRAVITREAL BEVACIZUMAB INJECTION FOR CENTRAL SEROUS CHORIORETINOPATHY
    Lim, Su Jin
    Roh, Mi In
    Kwon, Oh Woong
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (01): : 100 - 106
  • [23] Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo
    Lowe, John
    Araujo, James
    Yang, Jihong
    Reich, Mike
    Oldendorp, Amy
    Shiu, Vanessa
    Quarmby, Valerie
    Lowman, Henry
    Lien, Samantha
    Gaudreault, Jacques
    Maia, Mauricio
    [J]. EXPERIMENTAL EYE RESEARCH, 2007, 85 (04) : 425 - 430
  • [24] Lutty G, 1999, MOL VIS, V5
  • [25] A Pilot Study of Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes
    Margolis, Ron
    Spaide, Richard F.
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 147 (05) : 811 - 815
  • [26] Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
    Maruko, Ichiro
    Iida, Tomohiro
    Sugano, Yukinori
    Saito, Masaaki
    Sekiryu, Tetsuju
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 151 (04) : 594 - 603
  • [27] SUBFOVEAL CHOROIDAL THICKNESS AFTER TREATMENT OF VOGT-KOYANAGI-HARADA DISEASE
    Maruko, Ichiro
    Iida, Tomohiro
    Sugano, Yukinori
    Oyamada, Hiroshi
    Sekiryu, Tetsuju
    Fujiwara, Takamitsu
    Spaide, Richard F.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (03): : 510 - 517
  • [28] Choroidal Thickness Measured by Spectral Domain Optical Coherence Tomography Factors Affecting Thickness in Glaucoma Patients
    Maul, Eugenio A.
    Friedman, David S.
    Chang, Dolly S.
    Boland, Michael V.
    Ramulu, Pradeep Y.
    Jampel, Henry D.
    Quigley, Harry A.
    [J]. OPHTHALMOLOGY, 2011, 118 (08) : 1571 - 1579
  • [29] Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
    Mitchell, P.
    Korobelnik, J-F
    Lanzetta, P.
    Holz, F. G.
    Pruente, C.
    Schmidt-Erfurth, U.
    Tano, Y.
    Wolf, S.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (01) : 2 - 13
  • [30] Decreased arterial dye-filling and venous dilation in the macular choroid associated with age-related macular degeneration
    Mori, K
    Gehlbach, PL
    Nishiyama, Y
    Yoneya, S
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (04): : 430 - 437